ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value

$10.22+0.03 (+0.29%)

Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –

ImmuCell ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

ImmuCell's ebitda for the twelve months ending Sep 30, 2026 was $6.97M, up 37.1% year over year. For fiscal 2025 it was $4.43M, up 306.8% from the year before.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$4.43M	+306.8%
FY2024	Dec 31, 2024	$1.09M	–
FY2023	Dec 31, 2023	-$3.01M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$1.42M	+94.5%
Q2 FY2026	Jun 30, 2026	$2.41M	+92.7%
Q1 FY2026	Mar 31, 2026	$2.50M	+38.6%
Q4 FY2025	Dec 31, 2025	$651.52K	-50.1%
Q3 FY2025	Sep 30, 2025	$728.74K	+556.3%
Q2 FY2025	Jun 30, 2025	$1.25M	–
Q1 FY2025	Mar 31, 2025	$1.80M	–
Q4 FY2024	Dec 31, 2024	$1.31M	–
Q3 FY2024	Sep 30, 2024	$111.03K	–